OPEN END-TURBO-OPTIONSSCHEIN - NOVO NORDISK ADR B | Real-time BOERSE MUENCHEN 09:06:09 01/07/2024 pm IST | ||
| 5.09 EUR | -4.14% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 5.09 | -4.14% |
| 28/24/28 | 5.31 | +2.31% |
| 27/24/27 | 5.19 | -1.14% |
| 26/24/26 | 5.25 | +6.28% |
| 25/24/25 | 4.94 | -8.18% |
Real-time BOERSE MUENCHEN
Last update July 01, 2024 at 09:06 pm IST
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | HSBC |
| WKN | HS6UW3 |
| ISIN | DE000HS6UW38 |
| Date issued | 07/06/2024 |
| Strike | 199.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.65 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.54 € |
|---|---|
| Lowest since issue | 4.84 € |
| Spread | 0.01 € |
| Spread % | 0.19% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
